Compare Eni SpA (E) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eni SpA vs Summit Therapeutics Inc — how do they compare? Eni SpA trades at $55.89 (market cap $79.81B), while Summit Therapeutics Inc trades at $17.54 (market cap $13.71B). The key difference: Eni SpA is far larger — about 5.8× Summit Therapeutics Inc's market cap, and Eni SpA pays a 4.39% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eni SpA for 53 Days and Summit Therapeutics Inc for 16 Days on average.
| E | SMMT | |
|---|---|---|
Market Cap | $79.81B | $13.71B |
Volume | 365,912 | 6,173,057 |
Sector | Energy | Health |
52-Week High | $57.61 | $26.38 |
52-Week Low | $34.03 | $12.43 |
Typical Hold Time | 53 Days | 16 Days |
Enterprise Value | $104.34B | $13.04B |
Dividend Yield | 4.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $56.02, up 3.82% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows attractive valuation with a P/E of 12.87 and P/S of 0.85. Recent earnings have been mixed, with Q4 2025 beating estimates but Q1 and Q2 2026 missing. Revenue has declined from $132.5B in 2022 to $82.2B in 2025, though net income margin improved to 5.97% in 2026. Positive news includes expansion in Venezuela, Indonesia, and humanoid robotics partnerships.
Outlook is cautiously optimistic given low valuations and strategic initiatives, but risks include volatile energy prices and execution challenges. Analyst consensus is mixed with 34.6% buy ratings. Earnings growth and operational efficiency are key catalysts for upside, while geopolitical and macroeconomic factors pose headwinds.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
